REGULATION OF NF-KAPPA B/REL ACTIVITY IN T CELLS EXPRESSING THE TAX ONCOGENE OF HTLV-I (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

REGULATION OF NF-KAPPA B/REL ACTIVITY IN T CELLS EXPRESSING THE TAX ONCOGENE OF HTLV-I (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2188 1992. Unique Identifier : AIDSLINE ICDB/92684737
Lacoste J; Cohen L; Hiscott J; Molecular Oncology, Lady Davis Inst., McGill Univ., Montreal,; Quebec H3T 1E2, Canada

Abstract: The NF-kappa B/rel transcription complex represents a family of DNA-binding proto-oncogenes involved in transcriptional regulation of many immunomodulatory cytokines and cell surface receptors. The effect of the HTLV-I tax oncogene on NF-kappa B DNA-binding activity and NF-kappa B-dependent transcription was examined in tax-expressing Jurkat T cells. Stable expression of tax resulted in constitutive transcription of the endogenous GM-CSF gene and increased basal level of expression of transfected NF-kappa B-regulated promoters. In situ UV-cross-linking analyses of NF-kappa B protein-DNA complexes revealed the presence of several polypeptides ranging from 58 to 92 kD. Multiple forms of NF-kappa B were purified by DNA-affinity chromatography and shown to possess distinct DNA binding and gene activation properties using an in vitro transcription system. We are now investigating the interactions of recombinant NF-kappa B p50, p65 and c-rel with the tax protein and with the regulatory subunit I kappa B (inhibitor of NF-kappa B). These studies indicate that tax expression may alter the stoichiometry of NF-kappa B/rel proteins and change the expression of growth-regulated genes.

Keywords: Gene Products, tax/GENETICS *Genes, Regulator NF-kappa B/*GENETICS Recombinant Proteins/GENETICS Retroviridae Proteins, Oncogenic/*GENETICS T-Lymphocytes/*METABOLISM Transcription, Genetic/GENETICS ABSTRACT
920730
M9271104

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .